Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence

J Neurol Neurosurg Psychiatry. 2023 Nov;94(11):962-972. doi: 10.1136/jnnp-2021-328323. Epub 2023 Apr 4.

Abstract

Multiple pathological mechanisms are involved in the development of chemotherapy-induced peripheral neurotoxicity (CIPN). Recent work has provided insights into the molecular mechanisms underlying chemotherapy-induced axonal degeneration. This review integrates evidence from preclinical and clinical work on the onset, progression and outcome of axonal degeneration in CIPN. We review likely triggers of axonal degeneration in CIPN and highlight evidence of molecular pathways involved in axonal degeneration and their relevance to CIPN, including SARM1-mediated axon degeneration pathway. We identify potential clinical markers of axonal dysfunction to provide early identification of toxicity as well as present potential treatment strategies to intervene in axonal degeneration pathways. A greater understanding of axonal degeneration processes in CIPN will provide important information regarding the development and progression of axonal dysfunction more broadly and will hopefully assist in the development of successful interventions for CIPN and other neurodegenerative disorders.

Keywords: neuropathy; neurophysiology; oncology.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Antineoplastic Agents* / metabolism
  • Axons / pathology
  • Humans
  • Neurodegenerative Diseases* / pathology
  • Neurotoxicity Syndromes* / etiology

Substances

  • Antineoplastic Agents